Immunologically privileged cells and uses thereof

Details Immunologically privileged cells and uses thereof Immunologically privileged cells and uses thereof

2006-04-25

2006-04-25

Falk, Anne-Marie (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093200

Reexamination Certificate

active

07033585

ABSTRACT:
The invention is directed to immunologically privileged cells, e.g., autologous, allogeneic, and xenogeneic intermediate lobe pituitary cells, for delivering polypeptides, e.g., insulin, to a subject, and to methods of using the same.

REFERENCES:
Friedmann, T. (1997) Overcoming the obstacles to gene therapy. Sci. Am. Jun. 1997, pp. 96-101.
Orkin and Motulsky (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy.
Verma et al. (1997) Gene therapy—promises, problems and prospects. Nature 389: 239-242.
Halban et al. (2001) Gene and cell-replacement therapy in the treatment of type 1 diabetes. Diabetes 50: 2181-2191.
Welsh, N. (2000) Prospects for gene therapy of diabetes mellitus. Gene Therapy 7: 181-182.
Xu et al. (2003) Diabetes gene therapy: Potential and challenges. Current Gene Therapy 3(1): 65-82.
Harrison's Principles of Internal Medicine, 12th ed., Eds. J.D. Wilson et al., McGraw-Hill, Inc., NY, 1991, vol. 1, p. 43.
Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, 1990, pp. 1190-1191, 1281-1282, 1323-1324, 1342, 1509.
Anderson, WF, Nature, 392:25-30, 1998.
Dukes et al., Diabetes, 45(7):845-53, 1996.
Hughes et al., Proc. Nat'l. Acad. Sci., USA, 89:688-692, 1992.
Kaufman, J.E. et al., “Proinsulin Conversion in GH3 . . . ,” Diabetes, 46:978-982, 1997.
Ledley, F.D., Pharmaceutical Research, 13:1595-1614, 1996.
Lipes, M.A. et al., “Insulin-Secreting Non-Islet . . . ,” Proc. Nat'l. Acad. Sci., USA., 93:8595-8600, 1996.
Miller et al., FASEB J., 9:190-199.
Suzuki et al., Human Gene Therapy, 9:1223-1231.
Van Eyll et al., FEBs Letters, 348(1):7-13.
Zlokovic et al., Newrosurgery, 40(4):805-813.
Couzin, Islet transplants face test of time. Science 306(5693):34-7 (2004).
Motoyoshi et al., Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose. Diabetologia 41(12):1492-501 (1998).
The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England J. Med. 329:977-986 (1993).
Tremblay et al., Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 85(23):8890-4 (1988).
Zhang, Diabetes Care, Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. 24:1275-79 (2001).

Affiliated with

Also associated with

Rating

Immunologically privileged cells and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunologically privileged cells and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologically privileged cells and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3546702